Mesoblast Achieves Patient Treatment Target in Phase 3 Trial of Chronic Lower Back Pain

MT Newswires Live07-14

Mesoblast (ASX:MSB) achieved its target to treat at least 300 patients in a phase 3 trial of rexlemestrocel-L for chronic lower back pain linked to degenerative disc disease, according to a Tuesday filing with the Australian bourse.

The trial's primary endpoint targets a significant difference in the reduction of lower back pain between rexlemestrocel-L and sham controls after 12 months of treatment, while secondary endpoints include improvements in function, quality of life, and a halting of pain medications.

Rexlemestrocel-L obtained regenerative medicine advanced therapy designation from the US Food and Drug Administration, and the trial's topline results are due in mid-2027, the company said.

Mesoblast shares fell past 1% in recent Tuesday trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment